Caldera Therapeutics

Caldera Therapeutics, Inc. was founded in 2025 to drive the development of innovative biologics in the IBD field. The company has assembled a senior leadership team with extensive experience in IBD therapeutic discovery and development, as well as a proven track record in building biotech companies and achieving successful exits. Following a comprehensive evaluation of the dual-pathway ecosystem in IBD, Caldera obtained the global exclusive license for the development and commercialization of the bispecific antibody CLD-423 from Qyuns Therapeutics Co., Ltd.